InfuSystem Holdings (INFU) Cash from Financing Activities (2010 - 2026)
InfuSystem Holdings' (INFU) quarterly Cash from Financing Activities came in at -$790000.0 in Q1 2026, down 142.47% YoY from $1.9 million in Q1 2025, and up 70.77% on a QoQ basis from -$2.7 million in Q4 2025.
InfuSystem Holdings (INFU) Cash from Financing Activities (2010 - 2026) Analysis & Trends
InfuSystem Holdings (INFU) has 17 years of Cash from Financing Activities data on file, last reported at -$790000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 142.47% year-over-year to -$790000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.6 million (down 209.15% YoY) and the FY2025 annual result came in at -$15.0 million, down 116.05% from the prior year.
- Cash from Financing Activities rose to -$790000.0 in Q1 2026, from -$2.7 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $3.7 million in Q2 2024 to a low of -$8.0 million in Q3 2025.
- A 5-year average of -$2.0 million and a median of -$1.7 million in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 4117.35% — and 2024, when it surged 1679.15%.
- Tracing INFU's Cash from Financing Activities over 5 years: stood at -$1.7 million in 2022, then tumbled by 107.01% to -$3.5 million in 2023, then slipped by 27.4% to -$4.5 million in 2024, then soared by 40.13% to -$2.7 million in 2025, then soared by 70.77% to -$790000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$790000.0 (Q1 2026), -$2.7 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -213.50 Mn |
| 10 | InfuSystem Holdings | 244.87 Mn | 243.90 Mn | 21.41 Mn | -3.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.40 Mn |
| Jun 30, 2026 | -3.40 Mn |
| Mar 31, 2026 | -790,000.00 |
| Mar 31, 2026 | -790,000.00 |
| Dec 31, 2025 | -2.70 Mn |
| Dec 31, 2025 | -2.70 Mn |
| Sep 30, 2025 | -8.01 Mn |
| Sep 30, 2025 | -8.01 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Sep 30, 2024 | -6.75 Mn |
| Sep 30, 2024 | -6.75 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Mar 31, 2024 | 632,000.00 |
| Mar 31, 2024 | 632,000.00 |